Four (21%) had Notch pathway gain-of-function alterations, suggesting an ACC-I phenotype, whereas 10 (53%) had MYB–NFIB fusions or MYB amplification across both ACC phenotypes (Fig. 3A). The gene discussed is NFIB; the disease is adrenal cortex carcinoma.